Mirna Therapeutics, Inc. is First to Advance MicroRNA into the Clinic for Cancer
5/13/2013 10:28:20 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA (miRNA) replacement therapies for cancer, announced today that it has initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 trial is being conducted in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.
Help employers find you! Check out all the jobs and post your resume.
comments powered by